• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    US Stocks Mixed; Private Sector Payrolls Increase Less Than Expected

    11/1/23 9:42:28 AM ET
    $CLLS
    $IRIX
    $MNPR
    $PATI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CLLS alert in real time by email

    U.S. stocks traded mixed this morning, ahead of interest rate decision from the Federal Reserve.

    Following the market opening Wednesday, the Dow traded down 0.05% to 33,036.63 while the NASDAQ rose 0.32% to 12,892.45. The S&P 500 also rose, gaining, 0.15% to 4,199.94.

    Check This Out: $2.8M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying

     

    Leading and Lagging Sectors

     

    Information technology shares jumped by 0.5% on Wednesday.

    In trading on Wednesday, utilities shares fell by 0.3%.

     

    Top Headline

     

    Private businesses in the U.S. added 113,000 workers in October, compared to market estimates of a 150,000 increase and versus a gain of 89,000 in the prior month.

     

    Equities Trading UP

     

    Cellectis S.A. (NASDAQ:CLLS) shares shot up 154% to $2.45. Cellectis reported strategic collaboration and investment agreements with AstraZeneca. Cellectis also presented pre-clinical data on multi-armored allogeneic MUC1-CAR T-cells targeting triple-negative breast cancer at the Society for Immunotherapy of Cancer 38th Annual Meeting.

    Shares of Patriot Transportation Holding, Inc. (NASDAQ:PATI) got a boost, shooting 105% to $15.75. Patriot Transportation announced an agreement under which United Petroleum Transports will acquire all of the outstanding shares of Patriot common stock for $16.26 per share in cash.

    Monopar Therapeutics Inc. (NASDAQ:MNPR) shares were also up, gaining 42% to $0.6383. Monopar presented data showing tumor reduction benefit of camsirubicin from ongoing Phase 1b in patients with advanced soft tissue sarcoma at the 2023 Connective Tissue Oncology Society Annual Meeting.

     

    Equities Trading DOWN

     

    WeWork Inc. (NYSE:WE) shares dropped 50% to $1.1317 following reports that the company is nearing bankruptcy.

    Shares of IRIDEX Corporation (NASDAQ:IRIX) were down 45% to $1.82. Iridex has withdrawn its previously announced annual guidance for 2023 and plans to provide additional information during its third-quarter earnings release based on the information available at that time.

    Paycom Software, Inc. (NYSE:PAYC) was down, falling 37% to $154.05. Paycom Software reported worse-than-expected third-quarter sales results and issued FY23 revenue guidance below estimates.

    Also Check This Out: Top 3 Consumer Stocks That Could Sink Your Portfolio In Q4

     

    Commodities

     

    In commodity news, oil traded up 2.8% to $83.27 while gold traded up 0.1% at $1,996.10.

    Silver traded down 0.3% to $22.885 on Wednesday while copper rose 0.5% to $3.6665.

     

    Euro zone

     

    European shares were higher today. The eurozone’s STOXX 600 gained 0.5%, London’s FTSE 100 rose 0.4% while Spain’s IBEX 35 Index rose 0.4% The German DAX gained 0.4% French CAC 40 climbed 0.4%, while Italy’s FTSE MIB Index jumped 0.5%.

    The S&P Global/CIPS UK manufacturing PMI was revised lower to 44.8 in October from the preliminary reading of 45.2, while Nationwide House Price Index fell by 3.3% year-over-year in October.

     

    Asia Pacific Markets

     

    Asian markets closed mixed on Wednesday, with Japan’s Nikkei 225 rising 2.41%, Hong Kong’s Hang Seng Index falling 0.06% and China’s Shanghai Composite Index gaining 0.14%. India’s S&P BSE Sensex, meanwhile, slipped around 0.4%.

    Retail sales in Hong Kong surged 10.1% year-over-year in September versus a 11% increase in the prior month. The S&P Global India manufacturing PMI fell to 55.5 in October from 57.5, while the Caixin China general manufacturing PMI declined to 49.5 in October from 50.6 in the previous month. The au Jibun Bank Japan manufacturing PMI was revised higher to 48.7 in October.

     

    Economics

     

    Private businesses in the U.S. added 113,000 workers in October, compared to market estimates of a 150,000 increase and versus a gain of 89,000 in the prior month.

    Now Read This: These 3 Real Estate Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts

    Get the next $CLLS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLLS
    $IRIX
    $MNPR
    $PATI

    CompanyDatePrice TargetRatingAnalyst
    Monopar Therapeutics Inc.
    $MNPR
    1/9/2026$115.00Overweight
    Morgan Stanley
    Paycom Software Inc.
    $PAYC
    12/17/2025$195.00Buy
    BTIG Research
    Monopar Therapeutics Inc.
    $MNPR
    11/14/2025Strong Buy → Outperform
    Raymond James
    Monopar Therapeutics Inc.
    $MNPR
    11/10/2025$115.00Outperform
    Leerink Partners
    Monopar Therapeutics Inc.
    $MNPR
    10/13/2025$125.00Overweight
    Barclays
    Paycom Software Inc.
    $PAYC
    9/26/2025$270.00Buy
    Guggenheim
    Paycom Software Inc.
    $PAYC
    9/22/2025$258.00Hold → Buy
    TD Cowen
    Monopar Therapeutics Inc.
    $MNPR
    9/9/2025$87.00Buy
    BTIG Research
    More analyst ratings

    $CLLS
    $IRIX
    $MNPR
    $PATI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Iridex Announces Plans to Relocate Headquarters

    MOUNTAIN VIEW, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its intent to relocate the Company's headquarters from Mountain View, California to San Jose, California. On January 26, 2026, the Company signed a non-binding letter of intent for a new lease (the "Lease"). The Company plans to move to the 31,000 square feet location and is expecting to generate savings of approximately $0.4 million in fiscal year 2026 and approximately $0.6 million in savings on an annualized b

    2/2/26 7:00:00 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    New Study Proves Significant ROI from Paycom's Full-Solution Automation

    Paycom Software, Inc. (NYSE:PAYC) ("Paycom"), a leading provider of comprehensive, cloud-based human capital management software, today announced new findings from a Nucleus Research study highlighting the substantial value gained by organizations using Paycom's full‑solution automation. Among the organizations interviewed, primary benefits included avoided costs and increased productivity stemming from greater data visibility, the retirement of old systems and increased automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128582867/en/Paycom announced new findings from a Nucleus Research study highlighting the substant

    1/28/26 9:15:00 AM ET
    $PAYC
    Computer Software: Prepackaged Software
    Technology

    Jeff York Returns as Paycom's Chief Sales Officer

      Paycom Software, Inc. (NYSE:PAYC) ("Paycom"), a leading provider of comprehensive, cloud-based human capital management software, announced that Jeff York is returning to serve as chief sales officer (CSO), effective January 23, 2026. York previously served as CSO at Paycom from 2007 to 2021 and has since been serving as Paycom's Leadership Strategist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123915414/en/Jeff York Returns as Paycom's Chief Sales Officer York is replacing Amy Walker, who is transitioning from Paycom's CSO to a consulting role for the company. "Jeff is a proven sales strategist whose deep understan

    1/23/26 5:34:00 PM ET
    $PAYC
    Computer Software: Prepackaged Software
    Technology

    $CLLS
    $IRIX
    $MNPR
    $PATI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Dizon Romeo R bought $3,450 worth of shares (2,500 units at $1.38), increasing direct ownership by 2% to 115,190 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    2/3/26 6:21:19 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    New insider York Jeffrey D. claimed ownership of 238,330 shares (SEC Form 3)

    3 - Paycom Software, Inc. (0001590955) (Issuer)

    2/2/26 4:42:56 PM ET
    $PAYC
    Computer Software: Prepackaged Software
    Technology

    Chief Executive Officer Robinson Chandler acquired 62,815 shares (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    1/30/26 2:31:04 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLLS
    $IRIX
    $MNPR
    $PATI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Monopar Therapeutics Inc.

    SCHEDULE 13G/A - Monopar Therapeutics (0001645469) (Subject)

    2/6/26 9:54:43 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IRIDEX Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - IRIDEX CORP (0001006045) (Filer)

    1/12/26 9:11:03 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 6-K filed by Cellectis S.A.

    6-K - Cellectis S.A. (0001627281) (Filer)

    1/8/26 4:35:05 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLLS
    $IRIX
    $MNPR
    $PATI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Dizon Romeo R bought $3,450 worth of shares (2,500 units at $1.38), increasing direct ownership by 2% to 115,190 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    2/3/26 6:21:19 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Dizon Romeo R bought $1,588 worth of shares (1,101 units at $1.44), increasing direct ownership by 0.99% to 112,690 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    1/29/26 3:58:25 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Dizon Romeo R bought $1,898 worth of shares (1,300 units at $1.46), increasing direct ownership by 1% to 111,589 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    1/28/26 1:13:52 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CLLS
    $IRIX
    $MNPR
    $PATI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley initiated coverage on Monopar Therapeutics with a new price target

    Morgan Stanley initiated coverage of Monopar Therapeutics with a rating of Overweight and set a new price target of $115.00

    1/9/26 9:05:54 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research resumed coverage on Paycom Software with a new price target

    BTIG Research resumed coverage of Paycom Software with a rating of Buy and set a new price target of $195.00

    12/17/25 9:25:02 AM ET
    $PAYC
    Computer Software: Prepackaged Software
    Technology

    Monopar Therapeutics downgraded by Raymond James

    Raymond James downgraded Monopar Therapeutics from Strong Buy to Outperform

    11/14/25 9:54:47 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLLS
    $IRIX
    $MNPR
    $PATI
    Leadership Updates

    Live Leadership Updates

    View All

    Paycom promotes Shane Hadlock to lead IT; appoints Rachael Gannon to chief automation officer

    Brad Smith named senior technical strategist Paycom Software, Inc. (NYSE:PAYC) ("Paycom"), a leading provider of comprehensive, cloud-based human capital management software, today announced the expanded role of Shane Hadlock as Paycom's chief client officer and chief technology officer and the promotion of Rachael Gannon to chief automation officer, effective Aug. 18. Brad Smith has been named the company's senior technical strategist and will continue reporting to CEO Chad Richison. As chief technology officer, Hadlock will oversee Paycom's IT department, while maintaining his chief client officer role and leadership of Paycom's client service groups. "Shane's exceptional client-cen

    8/18/25 4:05:00 PM ET
    $PAYC
    Computer Software: Prepackaged Software
    Technology

    Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

    EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

    1/28/25 8:00:00 AM ET
    $CBUS
    $CLLS
    $MGX
    Agricultural Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics

    Monopar's pipeline includes clinical-stage radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease  NORTH CHICAGO, Ill., Jan. 23, 2025 /PRNewswire/ -- Rosalind Franklin University of Medicine and Science announced that Monopar Therapeutics is the latest biotech company to join the Helix 51 biomedical incubator community. Monopar, a clinical-stage biotechnology firm, is developing personalized and precise radiopharmaceuticals to diagnose and treat aggressive cancers, and will utilize the labs and other resources in Helix 51 t

    1/23/25 1:10:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLLS
    $IRIX
    $MNPR
    $PATI
    Financials

    Live finance-specific insights

    View All

    Paycom Software, Inc. Announces Fourth Quarter and Year-End 2025 Earnings Release Date and Conference Call

    Paycom Software, Inc. ("Paycom") (NYSE:PAYC), a leading provider of comprehensive, cloud-based human capital management software, will release its results for the fourth quarter and year-ended Dec. 31, 2025, after the market closes on Feb. 11. Paycom will also hold a conference call to discuss results at 5 p.m. (Eastern) that day. Dial-in #: +1 (833) 470-1428 Intl. Dial-In #: +1 (646) 844-6383 Access Code: 829388 Replay #: +1 (866) 813-9403 Intl. Replay #: +1 (929) 458-6194 Replay Access Code: 951764 The conference call will also be webcast at investors.paycom.com. For those unable

    1/21/26 4:05:00 PM ET
    $PAYC
    Computer Software: Prepackaged Software
    Technology

    Iridex Reports Third Quarter 2025 Financial Results

    MOUNTAIN VIEW, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended September 27, 2025. Third Quarter 2025 Financial Highlights Generated total revenue of $12.5 million, representing growth of 8% year-over-year compared to $11.6 million in the prior year quarterCyclo G6® product family revenue was $3.5 million, representing growth of 13% year-over-year compared to $3.1 million in the prior year quarter Sold 14,900 Cyclo G6 probes comp

    11/11/25 4:05:00 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Paycom Software, Inc. Reports Third Quarter 2025 Results

    Third Quarter Revenues of $493 million, up 9% year-over-year Third Quarter GAAP Net Income of $111 million, representing 22% of total revenues, or $1.96 per diluted share Third Quarter Non-GAAP Net Income of $110 million, or $1.94 per diluted share Third Quarter Adjusted EBITDA of $194 million, representing 39% of total revenues Paycom Software, Inc. ("Paycom," "we" and "our") (NYSE:PAYC), a leading provider of comprehensive, cloud-based human capital management software, today announced its financial results for the quarter ended September 30, 2025. "We delivered another strong quarter of double-digit organic recurring revenue growth and expanding margins," said Paycom founder, CEO an

    11/5/25 4:05:00 PM ET
    $PAYC
    Computer Software: Prepackaged Software
    Technology

    $CLLS
    $IRIX
    $MNPR
    $PATI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Monopar Therapeutics Inc.

    SC 13D/A - Monopar Therapeutics (0001645469) (Subject)

    12/17/24 5:01:42 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Paycom Software Inc.

    SC 13D/A - Paycom Software, Inc. (0001590955) (Subject)

    12/13/24 7:06:11 PM ET
    $PAYC
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G filed by Paycom Software Inc.

    SC 13G - Paycom Software, Inc. (0001590955) (Subject)

    11/14/24 4:07:41 PM ET
    $PAYC
    Computer Software: Prepackaged Software
    Technology

    $CLLS
    $IRIX
    $MNPR
    $PATI
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

    Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan

    6/22/24 8:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care